8-K: Current report filing
Published on March 6, 2019
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2019
Rexahn Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE
|
001-34079
|
11-3516358
|
|
(State or other jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (240) 268-5300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| |
Emerging growth company
|
☐
|
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying |
|
| with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 4, 2019, Ely Benaim, M.D. provided notice to Rexahn Pharmaceuticals, Inc. of his resignation as chief medical officer, effective March 31, 2019 to
accept the position of chief medical officer at a commercial stage, global oncology company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
REXAHN PHARMACEUTICALS, INC.
|
|
|
Date: March 6, 2019
|
/s/ Douglas J. Swirsky
|
|
Douglas J. Swirsky
|
|
|
President and Chief Executive Officer
|